DMTs may influence the natural history of MS . “It is important to provide our patients information about long-term prognosis, during the first months of therapy”, Dr Jordi Río (University Hospital Vall d’Hebron, Barcelona, Spain) advised. Although different scoring systems have been used in the assessment of response in the short-term, little data exists regarding the long-term predictive power of these scores [2,3]. There is evidence that MRI activity, relapses, and EDSS worsening are good predictors of short-term treatment response, i.e. during the first 2-3 years after initiation of therapy . Based on these clinical and imaging parameters, several scoring systems have been developed. Dr Río and colleagues compared different treatment response scoring systems to assess long-term prognosis in treated relapsing-remitting MS patients (n=319), and to describe diagnostic properties of the different scores.
Prediction model analysis showed that all scor...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« High Need for Biomarkers for Stage III Lung Cancer Next Article
Selpercatinib (LOXO-292) Shows Durable Activity in RET Fusion-positive Lung Cancer »
Table of Contents: ECTRIMS 2019
Towards a Comprehensive Assessment of MS Course
Monitoring and Treatment of Progressive MS
Optimising Long-Term Benefit of MS Treatment
Safety Assessment in the Post-Approval Phase
Pregnancy in the Treatment Era
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.